Cover Image
Market Research Report

Low Back Pain - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 255955
Published Content info 140 Pages
Delivery time: 1-2 business days
Price
Back to Top
Low Back Pain - Pipeline Review, H2 2019
Published: December 16, 2019 Content info: 140 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2019, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 14, 6, 4 and 1 respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11608IDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Low Back Pain - Overview
  • Low Back Pain - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Low Back Pain - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Low Back Pain - Companies Involved in Therapeutics Development
  • Ache Laboratorios Farmaceuticos SA
  • Adynxx Inc
  • Allodynic Therapeutics LLC
  • AnGes Inc
  • Axsome Therapeutics Inc
  • BioRestorative Therapies Inc
  • Bol Pharma
  • Camurus AB
  • Daewon Pharmaceutical Co Ltd
  • Frontier Biotechnologies Inc
  • Gador SA
  • Grunenthal GmbH
  • Hisamitsu Pharmaceutical Co Inc
  • Imbrium Therapeutics LP
  • Immune Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Intec Pharma Ltd
  • MD Biosciences GmbH
  • Mesoblast Ltd
  • Navipharm Co Ltd
  • Nektar Therapeutics
  • Pacira BioSciences Inc
  • Pfizer Inc
  • Qingdao Chia Tai Haier Pharmaceutical Co Ltd
  • Scilex Holding Co
  • Stayble Therapeutics AB
  • Sun Pharma Advanced Research Company Ltd
  • Therapix Biosciences Ltd
  • WEX Pharmaceuticals Inc
  • Low Back Pain - Drug Profiles
  • (aceclofenac + eperisone SR) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (acetaminophen + caffeine + diclofenac sodium + orphenadrine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (clonidine + naltrexone) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (eperisone + pelubiprofen) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (pregabalin PR + etoricoxib) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AK-1830 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AMG-0101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AYX-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BOLDPo-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BRTX-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bupivacaine ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • buprenorphine PR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cebranopadol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cyclobenzaprine hydrochloride SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dronabinol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dronabinol + palmidrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HP-3150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IG-8801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMB-9011010 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lidocaine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lidocaine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MD-22 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MPC-06ID - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxycodegol phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize ADORA2A for Arthritis Pain, Inflammation and Low Back Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STA-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STA-363 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tanezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tetrodotoxin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • zoledronate disodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Low Back Pain - Dormant Projects
  • Low Back Pain - Discontinued Products
  • Low Back Pain - Product Development Milestones
  • Featured News & Press Releases
  • Jul 25, 2019: Nektar Therapeutics recieves General Advice letter from the U.S. FDA for NKTR-181
  • Sep 18, 2018: Camurus announces positive topline phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain
  • Jun 14, 2018: New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting
  • Jun 13, 2018: Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS)
  • May 31, 2018: Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy
  • Mar 29, 2018: Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
  • Mar 20, 2018: Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
  • Feb 27, 2018: AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
  • Sep 25, 2017: Mesoblast Provides Update on lead product candidate MPC-06-ID at Global Healthcare Conferences
  • Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
  • Apr 25, 2017: AnGes Announces FDA Clearance of Investigational New Drug Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain
  • Mar 24, 2017: AnGes: Investigational New Drug (IND) Application Submitted to the FDA
  • Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain
  • Mar 15, 2017: Durable Three-Year Outcomes In Degenerative Disc Disease After a Single Injection of Mesoblast's Cell Therapy
  • Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Low Back Pain, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2019
  • Low Back Pain - Pipeline by Adynxx Inc, H2 2019
  • Low Back Pain - Pipeline by Allodynic Therapeutics LLC, H2 2019
  • Low Back Pain - Pipeline by AnGes Inc, H2 2019
  • Low Back Pain - Pipeline by Axsome Therapeutics Inc, H2 2019
  • Low Back Pain - Pipeline by BioRestorative Therapies Inc, H2 2019
  • Low Back Pain - Pipeline by Bol Pharma, H2 2019
  • Low Back Pain - Pipeline by Camurus AB, H2 2019
  • Low Back Pain - Pipeline by Daewon Pharmaceutical Co Ltd, H2 2019
  • Low Back Pain - Pipeline by Frontier Biotechnologies Inc, H2 2019
  • Low Back Pain - Pipeline by Gador SA, H2 2019
  • Low Back Pain - Pipeline by Grunenthal GmbH, H2 2019
  • Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2019
  • Low Back Pain - Pipeline by Imbrium Therapeutics LP, H2 2019
  • Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, H2 2019
  • Low Back Pain - Pipeline by Inspyr Therapeutics Inc, H2 2019
  • Low Back Pain - Pipeline by Intec Pharma Ltd, H2 2019
  • Low Back Pain - Pipeline by MD Biosciences GmbH, H2 2019
  • Low Back Pain - Pipeline by Mesoblast Ltd, H2 2019
  • Low Back Pain - Pipeline by Navipharm Co Ltd, H2 2019
  • Low Back Pain - Pipeline by Nektar Therapeutics, H2 2019
  • Low Back Pain - Pipeline by Pacira BioSciences Inc, H2 2019
  • Low Back Pain - Pipeline by Pfizer Inc, H2 2019
  • Low Back Pain - Pipeline by Qingdao Chia Tai Haier Pharmaceutical Co Ltd, H2 2019
  • Low Back Pain - Pipeline by Scilex Holding Co, H2 2019
  • Low Back Pain - Pipeline by Stayble Therapeutics AB, H2 2019
  • Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
  • Low Back Pain - Pipeline by Therapix Biosciences Ltd, H2 2019
  • Low Back Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2019
  • Low Back Pain - Dormant Projects, H2 2019
  • Low Back Pain - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Low Back Pain - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Low Back Pain, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top